Zinc Supplementation and Inflammation in Older Medical Patients
Condition(s) studied
Investigational drug(s) / intervention(s)
Zinc Supplement: 22 mg Zinc supplementation daily for 12 months
Study summary
The hypothesis is that a daily supplement of 22 mg of zinc over 12 months can reduce in-flammatory biomarkers in acutely hospitalized older adults aged ≥ 65 years.
The aims are to determine, in acutely hospitalized older adults aged ≥ 65 years, if a daily supplement of 22 mg of zinc over 12 months compared to control can decrease inflammato-ry biomarkers, reduce symptoms of self-reported infection, reduce readmission and mortali-ty, increase QoL, increase physical performance, investigate potential adverse events to zinc supplement, and the changes in inflammatory biomarkers. It will also be studied if albumin-corrected zinc in plasma is a more accurate method for assessing zinc status than ordinary plasma zinc.
Eligibility
Primary outcome measure(s)
- inflammation 6 months — 6 months
To evaluate the difference between the groups in plasma concentrations of IL-6 during the first 6-months. Endpoints: Plasma concentration of IL-6 (pg/ml) from baseline to 6 months
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Herlev Hospital | Herlev | Region Hovedstad | Recruiting |
More Herlev Hospital trials in Denmark
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07672132 on ClinicalTrials.gov ↗ ← All trials in Denmark